Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
A 2-year extension to study 2203, partially randomized, double-blind, placebo-controlled in the first year and open label in the second year, to assess the safety of the dose of AAE581 selected for phase III development in postmenopausal osteoporosis, and the offset of effect on biomarkers and BMD https://kusajili.fr:443/Trial/ZqHaB_-YbEWx8ufwaCBQhQ%24a-2-year-extension-to-study-2203-partially-randomized-double-blind-placebo-controlled-in-the-first-year-and-open-label-in-the-s
I have read and accept the terms of use of the site and the Privacy Policy
Send your message